Qiagen Sees FY24 EPS $2.16 Vs $2.12 Est.; Revenue $1.985B Vs $2B Est.
Portfolio Pulse from Benzinga Newsdesk
QIAGEN has updated its FY 2024 outlook, projecting EPS of $2.16 versus the estimated $2.12, and revenue of $1.985 billion versus the estimated $2 billion. The update is based on strong core business performance and the decision to phase out the NeuMoDx clinical PCR system.
July 31, 2024 | 8:27 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
QIAGEN has updated its FY 2024 outlook, projecting EPS of $2.16 versus the estimated $2.12, and revenue of $1.985 billion versus the estimated $2 billion. The update is based on strong core business performance and the decision to phase out the NeuMoDx clinical PCR system.
The increase in EPS and solid revenue projection, despite being slightly below estimates, indicates strong core business performance. The decision to phase out the NeuMoDx system suggests a strategic shift that could improve margins.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100